CN116676263A - 冻存pbmc诱导nk细胞的培养试剂盒及使用方法 - Google Patents
冻存pbmc诱导nk细胞的培养试剂盒及使用方法 Download PDFInfo
- Publication number
- CN116676263A CN116676263A CN202310719309.5A CN202310719309A CN116676263A CN 116676263 A CN116676263 A CN 116676263A CN 202310719309 A CN202310719309 A CN 202310719309A CN 116676263 A CN116676263 A CN 116676263A
- Authority
- CN
- China
- Prior art keywords
- culture
- cells
- culture solution
- peripheral blood
- pbmc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 title claims abstract description 31
- 238000000034 method Methods 0.000 title claims abstract description 22
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 14
- 230000008014 freezing Effects 0.000 title claims abstract description 10
- 238000007710 freezing Methods 0.000 title claims abstract description 10
- 230000003213 activating effect Effects 0.000 claims abstract description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000004113 cell culture Methods 0.000 claims abstract description 6
- 229910001415 sodium ion Inorganic materials 0.000 claims abstract description 6
- 230000004913 activation Effects 0.000 claims abstract description 5
- BQRXMLXVGQMIBO-UHFFFAOYSA-N 1,1-bis(sulfanyl)ethanol Chemical compound CC(O)(S)S BQRXMLXVGQMIBO-UHFFFAOYSA-N 0.000 claims abstract description 4
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 claims abstract description 4
- 108090000695 Cytokines Proteins 0.000 claims abstract description 4
- 102000004127 Cytokines Human genes 0.000 claims abstract description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 4
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims abstract description 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 4
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 4
- 229930182816 L-glutamine Natural products 0.000 claims abstract description 4
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 4
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 4
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000005516 coenzyme A Substances 0.000 claims abstract description 4
- 229940093530 coenzyme a Drugs 0.000 claims abstract description 4
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 claims abstract description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960000905 indomethacin Drugs 0.000 claims abstract description 4
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims abstract description 4
- 108010082117 matrigel Proteins 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims abstract description 4
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 4
- 238000003259 recombinant expression Methods 0.000 claims abstract description 4
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 4
- 239000011718 vitamin C Substances 0.000 claims abstract description 4
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 4
- 229940046009 vitamin E Drugs 0.000 claims abstract description 4
- 239000011709 vitamin E Substances 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 9
- 210000005259 peripheral blood Anatomy 0.000 claims description 6
- 239000011886 peripheral blood Substances 0.000 claims description 6
- 210000004748 cultured cell Anatomy 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 210000002865 immune cell Anatomy 0.000 abstract description 7
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 abstract description 4
- 230000003321 amplification Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 3
- 239000012531 culture fluid Substances 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 description 4
- 239000007640 basal medium Substances 0.000 description 3
- 210000004405 cytokine-induced killer cell Anatomy 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/40—Nucleotides, nucleosides, bases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/53—CD2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明属于生物医学技术领域，公开了一种冻存PBMC诱导NK细胞的培养试剂盒及使用方法，培养试剂盒，包括基础培养液和激活培养液；基础培养液包括1640细胞培养基质胶和重组表达蛋白冻干粉；激活培养液包括人血白蛋白、人血清蛋白、维生素C、维生素E、辅酶A、重组人胰岛素、L‑谷氨酰胺、二巯基乙醇、吲哚美辛、钠离子(Na+)、单克隆抗体CD2、OK432、细胞因子、IL‑2。本发明的培养试剂盒，制备方便、成本较低；对本身活性较差的免疫细胞，如NK细胞也能达到较好的扩增激活效果，具有十分良好的生物安全性。
Description
技术领域
本发明属于生物医学技术领域，具体涉及一种冻存PBMC诱导NK细胞的培养试剂盒及使用方法。
背景技术
PBMC细胞，即外周血单个核细胞(Peripheralbloodmononuclearcell)可以在适当条件下，在体外诱导分化成免疫细胞，并进一步向目标类型细胞进行定向分化，如自然杀伤(NK)细胞、细胞因子诱导的杀伤细胞(CIK)、树突状细胞(DC)等。由于PBMC细胞直接由患者的外周血而来，所以在进行细胞移植的时候不存在免疫排斥，且不用考虑细胞来源的伦理问题。临床应用免疫细胞存在供应不足的情况，目前对免疫细胞诱导分化的研究包括细胞共培养技术或添加培养基等方法，但这些方法存在诱导成功的细胞数目少、分化效率低、易受病原污染的缺点。
发明内容
为了解决现有技术存在的上述问题，本发明目的在于提供一种冻存PBMC诱导NK细胞的培养试剂盒及使用方法。
本发明所采用的技术方案为：
一种冻存PBMC诱导NK细胞的培养试剂盒，包括基础培养液和激活培养液；
基础培养液包括1640细胞培养基质胶和重组表达蛋白冻干粉；基础培养液能够有效诱导PBMC的分化，显著减少PBMC细胞的凋亡；
激活培养液包括人血白蛋白、人血清蛋白、维生素C、维生素E、辅酶A、重组人胰岛素、L-谷氨酰胺、二巯基乙醇、吲哚美辛、钠离子(Na+)、单克隆抗体CD2、OK432、细胞因子、IL-2；激活培养液能够促进免疫细胞早期的增殖分化，能够获得高数量、高纯度免疫细胞。
优选地，激活培养液的添加量为基础培养液的3～5％。
上述的冻存PBMC诱导NK细胞的培养试剂盒的使用方法，包括以下步骤：
获取外周血单个核细胞；
将基础培养液铺于培养皿中；
将经过计数的外周血单个核细胞加入培养皿中，并在预设温度培养；
培养24小时后更换激活培养液，并每2天对培养皿中的细胞进行半换液。
优选地，获取外周血后利用淋巴细胞分离管分离并获取外周血中的外周血单个核细胞。
优选地，所述培养皿为六孔板，每孔中基础培养液的量为0.5mL，每孔中外周血单个核细胞的量为1.5mL。
优选地，将基础培养液铺于培养皿中后，将培养皿置于培养箱中37℃条件放置30分钟，使其温度上升至37℃或接近37℃度。
优选地，所述预设温度为37℃。
优选地，每7天对培养的细胞进行观察，记录观察结果。
本发明的有益效果为：
本发明所提供的冻存PBMC诱导NK细胞的培养试剂盒，制备方便、成本较低；使用方便，扩增效率好；无引起过敏、严重炎症和肿瘤等生物安全风险；对本身活性较差的免疫细胞，如NK细胞也能达到较好的扩增激活效果；具有十分良好的生物安全性，极具产业化潜力和应用价值。
本发明所提供的培养试剂盒的使用方法，操作简单方便，能够大大降低操作人员的操作难度，从而提高操作效率，且不需要用到特别复杂的仪器以及试剂等，降低了操作成本。
具体实施方式
下面结合具体实施例对本发明做进一步阐释。需要说明的是，在不冲突的情况下，本发明中的实施例及实施例中的特征可以相互组合。
本实施例提供一种冻存PBMC诱导NK细胞的培养试剂盒，包括基础培养液和激活培养液；基础培养液包括1640细胞培养基质胶和重组表达蛋白冻干粉；激活培养液包括人血白蛋白、人血清蛋白、维生素C、维生素E、辅酶A、重组人胰岛素、L-谷氨酰胺、二巯基乙醇、吲哚美辛、钠离子、单克隆抗体CD2、OK432、细胞因子、IL-2。培养试剂盒使用时，激活培养液的添加量为基础培养液的3～5％(体积比)。
本实施例提供一种上述培养试剂盒的使用方法，包括以下步骤：获取健康志愿者外周血15mL，利用淋巴细胞分离管分离其中的外周血单个核细胞。将基础培养液铺于六孔板中，每孔中基础培养液的量为0.5mL，将六孔板置于培养箱中37℃条件放置30分钟可进行后续使用。将经过计数的外周血单个核细胞加入铺有基础培养液的六孔板中，每孔中外周血单个核细胞的量为1.5mL，并置于培养箱中37℃条件培养。培养24小时后更换激活培养液，并每2天对六孔板中的细胞进行半换液，每7天对培养的细胞进行观察，记录观察结果。结果显示14天时达到最佳扩增效果。
本发明不局限于上述可选的实施方式，任何人在本发明的启示下都可得出其他各种形式的产品。上述具体实施方式不应理解成对本发明的保护范围的限制，本发明的保护范围应当以权利要求书中界定的为准，并且说明书可以用于解释权利要求书。
Claims (8)
1.一种冻存PBMC诱导NK细胞的培养试剂盒，其特征在于：
包括基础培养液和激活培养液；
基础培养液包括1640细胞培养基质胶和重组表达蛋白冻干粉；
激活培养液包括人血白蛋白、人血清蛋白、维生素C、维生素E、辅酶A、重组人胰岛素、L-谷氨酰胺、二巯基乙醇、吲哚美辛、钠离子、单克隆抗体CD2、OK432、细胞因子、IL-2。
2.如权利要求1所述的冻存PBMC诱导NK细胞的培养试剂盒，其特征在于：激活培养液的添加量为基础培养液的3～5％。
3.如权利要求1或2所述的冻存PBMC诱导NK细胞的培养试剂盒的使用方法，其特征在于，包括以下步骤：
获取外周血单个核细胞；
将基础培养液铺于培养皿中；
将经过计数的外周血单个核细胞加入培养皿中，并在预设温度培养；
培养24小时后更换激活培养液，并每2天对培养皿中的细胞进行半换液。
4.如权利要求3所述的培养试剂盒的使用方法，其特征在于：获取外周血后利用淋巴细胞分离管分离并获取外周血中的外周血单个核细胞。
5.如权利要求3所述的培养试剂盒的使用方法，其特征在于：所述培养皿为六孔板，每孔中基础培养液的量为0.5mL，每孔中外周血单个核细胞的量为1.5mL。
6.如权利要求3所述的培养试剂盒的使用方法，其特征在于：将基础培养液铺于培养皿中后，将培养皿置于培养箱中37℃条件放置30分钟。
7.如权利要求3所述的培养试剂盒的使用方法，其特征在于：所述预设温度为37℃。
8.如权利要求3所述的培养试剂盒的使用方法，其特征在于：每7天对培养的细胞进行观察，记录观察结果。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310719309.5A CN116676263A (zh) | 2023-06-16 | 2023-06-16 | 冻存pbmc诱导nk细胞的培养试剂盒及使用方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310719309.5A CN116676263A (zh) | 2023-06-16 | 2023-06-16 | 冻存pbmc诱导nk细胞的培养试剂盒及使用方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116676263A true CN116676263A (zh) | 2023-09-01 |
Family
ID=87785297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310719309.5A Pending CN116676263A (zh) | 2023-06-16 | 2023-06-16 | 冻存pbmc诱导nk细胞的培养试剂盒及使用方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116676263A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116875548A (zh) * | 2023-09-08 | 2023-10-13 | 山东康华生物医疗科技股份有限公司 | 一种nk细胞活性培养管及其生产工艺 |
| CN117562049A (zh) * | 2023-11-22 | 2024-02-20 | 深圳泽医细胞治疗集团有限公司 | 基于γδT细胞培养的血液保存液及其应用 |
-
2023
- 2023-06-16 CN CN202310719309.5A patent/CN116676263A/zh active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116875548A (zh) * | 2023-09-08 | 2023-10-13 | 山东康华生物医疗科技股份有限公司 | 一种nk细胞活性培养管及其生产工艺 |
| CN116875548B (zh) * | 2023-09-08 | 2024-01-02 | 山东康华生物医疗科技股份有限公司 | 一种nk细胞活性培养管及其生产工艺 |
| CN117562049A (zh) * | 2023-11-22 | 2024-02-20 | 深圳泽医细胞治疗集团有限公司 | 基于γδT细胞培养的血液保存液及其应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116676263A (zh) | 冻存pbmc诱导nk细胞的培养试剂盒及使用方法 | |
| CN102154206B (zh) | 一种高纯度、高增殖力、高细胞毒活性的cik细胞的制备方法 | |
| CN102676454B (zh) | 一种脐带血来源的cik细胞的制备方法 | |
| CN105754942A (zh) | 一种体外扩增nk细胞的方法及其获得的nk细胞 | |
| CN102816735B (zh) | 一种自体外周血淋巴细胞的培养方法 | |
| CN102978161A (zh) | Dc-cik细胞分离培养试剂盒及其应用 | |
| CN101514333B (zh) | 一种免疫耐受型树突状细胞及其制备方法与专用培养基 | |
| CN104711225A (zh) | Nk细胞的体外制备方法 | |
| CN116376828B (zh) | 一种诱导CD4+T细胞生成Treg细胞的方法及应用 | |
| CN111826348A (zh) | 一种人诱导性多能干细胞来源的间充质干细胞体外高效制备方法和应用 | |
| Yang et al. | Decreased immunomodulatory and secretory capability of aging human umbilical cord mesenchymal stem cells in vitro | |
| CN110195041B (zh) | 利用ASC三维培养体系获得高活性Tregs细胞的方法 | |
| CN115558641A (zh) | 高纯度效应免疫细胞群及其培养方法、试剂组合物和应用 | |
| CN111117958A (zh) | 一种人外周血调节性t细胞的体外扩增试剂盒及扩增方法 | |
| CN111172110B (zh) | 一种脐带血cik细胞的培养方法 | |
| CN109486758A (zh) | 一种外周血nk细胞体外高效扩增试剂及操作说明 | |
| CN111235107B (zh) | 一种用于免疫细胞培养的添加剂、培养基及免疫细胞的培养方法 | |
| CN104109653A (zh) | 利用无动物血清培养体系大规模扩增人外周血dnt细胞的方法 | |
| CN111849892A (zh) | 一种胶质瘤来源肿瘤浸润淋巴细胞（til）的体外扩增方法及用途 | |
| CN110857435B (zh) | 用于培养从脐血中分离的免疫细胞的培养基及其培养方法 | |
| CN106701680A (zh) | 一种促进树突状细胞成熟的组合因子及培养树突状细胞的方法 | |
| CN115521914A (zh) | 一种人原代自然杀伤细胞体外扩增体系及方法 | |
| CN107090434B (zh) | 一种提高cik细胞培养效果的血液抗凝和保存方法 | |
| CN112300992B (zh) | 一种nk细胞培养液及多级激活nk细胞的培养方法 | |
| CN118291376A (zh) | 细胞外囊泡在制备缓解iPSC-MSCs复制性衰老的培养基中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |